Brain+ (BRAINP) Stock Overview

Brain+ A/S develops digital therapeutics for Alzheimer's and dementia. The company's product pipeline includes cognitive stimulation therapy (CST) - Therapist Companion, an application that enables therapists to deliver CST while saving significant preparation time; CST - Home Companion, a digital health application to provide repeat exposure to the CST program in an at-home setting during and after participation in a therapist facilitated CST program; CST - Home Care, a solution to enable people with dementia to continue to receive maintenance benefits from CST therapy after completion of the seven-week basic CST group program; and CST for mild cognitive impairment (MCI), a solution for individuals with MCI, offering an adapted version of CST to address their unique needs. It also develops Computerized Cognitive Training, a cognitive training method for patients with mild cognitive impairment; and Starry Night, a memory test designed to identify early signs of Alzheimer's disease. The company was incorporated in 2012 and is based in Copenhagen, Denmark.